NCT06143267Completed
Neuronostatin - a Glucagonotropic Agent in Humans?
Source: ClinicalTrials.gov · Last updated 10 Dec 2024
Brief summary (registry, in English)
With the present study the investigators wish to delineate the effects of neuronostatin-13 (NST) on glucose-dependent glucagon secretion in humans. The main question it aims to answer is: • What are the physiological effects of the naturally occuring hormone NST - especially with regards to glucagonotropic effects at different plasma glucose concentrations In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 9 Nov 2023
- Start date
- 6 Dec 2022
- Primary completion date
- 25 Sept 2024
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Type 1 diabetes
- NCT number
- NCT06143267
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From 6 Dec 2022 to the primary completion date, 25 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with any medication that cannot be paused for 12 hours
Other illness
- Diabetes
- Any condition that the investigator feels would interfere with trial participation
Lab values
- Treatment with drugs that might interfere with glucose metabolism within a month prior to the research study
- Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 × normal values
- Nephropathy (eGFR \<60 ml/min and/or albuminuria)
Who the study is looking for
- Normal haemoglobin \>8.3 mmol/l
- Normal fasting plasma glucose below 7 mmol/l
- Normal HbA1C \<42 mmol/mol (6%)
- Body mass index (BMI) 18.5-27 kg/m2
- Oral and written informed consent
Age in the registry: 18 years to 65 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.